<DOC>
	<DOCNO>NCT00017472</DOCNO>
	<brief_summary>Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Phase I trial study effectiveness monoclonal antibody therapy treat patient chronic lymphocytic leukemia , lymphocytic lymphoma , acute lymphoblastic leukemia , acute myeloid leukemia .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Chronic Lymphocytic Leukemia , Lymphocytic Lymphoma , Acute Lymphoblastic Leukemia , Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) biological effective dose monoclonal antibody Hu1D10 ( apolizumab ) patient previously treat chronic lymphocytic leukemia small lymphocytic lymphoma . II . Determine safety drug , term frequency severity treatment-related adverse event , patient population . SECONDARY OBJECTIVES : I . Determine whether drug anti-leukemia/lymphoma activity patient express Hu1D10 antigen . II . Determine pharmacokinetics drug patient population . III . Determine whether infusion-related toxicity drug secondary cytokine release patient . IV . Determine whether intensity 1D10 target antigen tumor cell related clinical response treatment toxicity patient . V. Determine pharmacodynamics drug patient population . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord diagnosis ( chronic lymphocytic leukemia small lymphocytic lymphoma v acute lymphoblastic leukemia [ ALL ] acute myeloid leukemia [ AML ] ) . Patients ALL AML enrol maximum tolerate dose ( MTD ) determine . Patients receive apolizumab IV least 2 hour day 1 , 2 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 . Treatment continue absence disease progression unacceptable toxicity . Patients complete partial response relapse 2 month may receive additional course therapy provide still express 1D10 antigen . Cohorts 3-6 patient receive escalate dos MOAB Hu1D10 MTD determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity ( DLT ) . If DLT observe , biological effective dose ( BED ) determine cohort . The BED define dose least 4 6 patient experience acceptable minimum trough level clinical response . An additional 24 patient ( 12 per stratum ) treat MTD . Patients follow 1 week , 1 2 month , every 3 month 1 year . PROJECTED ACCRUAL : A total 35 patient ( 12 per stratum ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>One follow diagnosis : Histologically confirm chronic lymphocytic leukemia ( CLL ) noncontiguous stage II stage IIIIV small lymphocytic lymphoma ( SLL ) Previously treat least 1 form chemotherapy immunotherapy Histologically confirm acute lymphoblastic leukemia ( enrolled maximum tolerate dose ( MTD ) determine ) Must fail 1 prior therapy Ineligible allogeneic stem cell transplantation Histologically confirm acute myeloid leukemia ( enrol MTD determine ) Primary refractory relapse ( within past year ) disease Ineligible potential curative therapy Express Hu1D10 antigen Greater 2 time mean fluorescence intensity control flow cytometry ( blood bone marrow cell ) OR Positive immunohistochemical staining ( lymph node ) Presenting one follow indication treatment unless early bone marrow transplantation plan ( CLL SLL patient ) : Diseaserelated progressive symptom Progressively worsen anemia thrombocytopenia Progressively worsen lymphadenopathy Massive splenomegaly hypersplenism Hyperlymphocytosis ( WBC great 200,000/mm3 ) lymphocyte double time le 12 month Marrow failure secondary marrow infiltration leukemia lymphoma Performance status ECOG 02 At least 2 year See Disease Characteristics Platelet count least 50,000/mm^3 ( without transfusion ) Bilirubin great 3 mg/dL ( unless elevate secondary tumor ) Creatinine great 2.0 mg/dL No prior decompensated congestive heart failure , unstable angina , myocardial infarction within past 6 month correct percutaneous transluminal coronary angioplasty surgery No active infection require oral IV antibiotic No malignancy would limit life expectancy HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study See Disease Characteristics At least 1 month since prior rituximab alemtuzumab ( unless CD20 CD52 antigen express tumor cell ) No prior monoclonal antibody Hu1D10 See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>